Impact of SARS-CoV-2 infection on pain crisis and acute chest syndrome in patients with sickle cell anemia: A retrospective multi-cohort study based on US national data from 2020 to 2022.
COVID‐19
SARS‐Cov‐2
acute chest syndrome
pain
sickle cell anaemia
sickle cell disease
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
06
09
2023
revised:
28
11
2023
accepted:
04
12
2023
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
epublish
Résumé
COVID-19 infection has been a significant contributor to global morbidity and mortality, especially among those patients with chronic diseases. The Centers for Disease Control and Prevention have classified sickle cell disease (SCD) as a condition that increases the risk of severe illness from COVID-19 infection. A retrospective study was conducted using the TRiNetX health research network database to identify SCA patients ( HbSS, Sbeta-thalassemia zero) who had SARS-CoV-2 infection over 2 years; these were compared with similar patients who did not have the infection in terms of demographics, pain control, and laboratory parameters COVID-19 illness impacts [ain crises and ACS, and prior vaccination against influenza and COVID-19 may represent a protective factor for developing pain crises.
Identifiants
pubmed: 38633124
doi: 10.1002/jha2.840
pii: JHA2840
pmc: PMC11020112
doi:
Types de publication
Journal Article
Langues
eng
Pagination
299-307Informations de copyright
© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.